This site is intended for Healthcare Professionals only.

Scottish Medicines Consortium accepts Ponvory to treat relapsing multiple sclerosis

Date:

Share post:

The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the Scottish Medicines Consortium (SMC) has approved Ponvory (ponesimod) for treating adults with relapsing-remitting multiple sclerosis (RRMS) within NHS Scotland.

Ponesimod offers an additional treatment choice for the ailment, which affects over 15,000 people in Scotland.

Multiple sclerosis (MS) is a chronic autoimmune inflammatory disease of the central nervous system in which immune cells attack myelin, causing inflammation.

The common symptoms of this disease include fatigue, balance and walking problems, numbness or tingling, dizziness and vertigo.

Amanda Cunnington, director of Health Economics, Market Access, Reimbursement, Government Affairs & Patient Engagement, Janssen-Cilag Limited said: “This decision further supports our commitment to ensuring patients living with this condition have access to new treatment options to help address some of the life-long and life-limiting symptoms of MS.

“We will work closely with the SMC and NHS Scotland to ensure that ponesimod will be available for eligible patients as quickly as possible.”

The SMC’s advice is based on data from the Phase III OPTIMUM trial, a multicenter, randomised, double-blind, parallel-group, active-controlled superiority study of 1,133 patients with relapsing multiple sclerosis (RMS) aged 18-55 years, in 28 countries.

The trial aimed to evaluate the efficacy and safety of the once-daily oral treatment of ponesimod (20 mg) against the once-daily teriflunomide (14 mg), an approved and established first-line oral treatment.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Current Issue June 2024

Related articles

How pharmacists can help children and young people with asthma: 2024 AskAboutAsthma campaign highlights

The 2024 #AskAboutAsthma campaign calls on pharmacists to take an active role in improving asthma management and outcomes...

Huxley Europe relaunches HuxQ10 Capsules with triple certification

The relaunch underscores Huxley Europe's commitment to health and welfare, offering specially developed formulas for users with dietary...

Alastair Buxton outlines vision for Community Pharmacy at Westminster Health Forum

Alastair Buxton, Director of NHS Services at CPE, outlines critical issues and solutions at the Westminster Health Forum,...

Food prices remain UK consumers’ top concern, FSA report finds

Consumers worried about food affordability were more likely to take food safety risks to save money The Food...